Galavit 50 mg 5 pcs. injection solution for intramuscular administration Selvim 1/5

Nosological classification (ICD-10)

A04.9 Bacterial intestinal infection, unspecified
A09 Diarrhea and gastroenteritis of presumably infectious origin (dysentery, bacterial diarrhea)
A41.8 Other specified septicemia
A46 Erysipelas
A48.3 Toxic shock syndrome
A56.0 Chlamydial infections of the lower genitourinary tract
A56.2 Chlamydial infection of the genitourinary tract, unspecified
A59.0 Urogenital trichomoniasis
B00 Infections caused by herpes simplex virus
B19 Viral hepatitis, unspecified
B34 Viral infection of unspecified localization
B97.7 Papillomaviruses
D26 Other benign neoplasms of the uterus
D84.9 Immunodeficiency, unspecified
E63 Physical and mental overload
F06.6 Organic emotionally labile [asthenic] disorder
F10 Mental and behavioral disorders caused by alcohol use
F10.3 Withdrawal state
F11 Mental and behavioral disorders caused by opioid use
F12 Mental and behavioral disorders caused by cannabinoid use
F45 Somatoform disorders
F48 Other neurotic disorders
F48.0 Neurasthenia
G90 Disorders of the autonomic nervous system
H66.9 Otitis media, unspecified
J02 Acute pharyngitis
J02.9 Acute pharyngitis, unspecified
J06 Acute upper respiratory tract infections of multiple and unspecified localization
J18 Pneumonia without specifying the pathogen
J31.2 Chronic pharyngitis
J35.0 Chronic tonsillitis
J35.2 Adenoid hypertrophy
J35.9 Chronic disease of tonsils and adenoids, unspecified
J39.9 Upper respiratory tract disease, unspecified
J40 Bronchitis, not specified as acute or chronic
J86 Pyothorax
J98.8 Other specified respiratory disorders
K05.6 Periodontal disease, unspecified
K12 Stomatitis and related lesions
K13.7 Other and unspecified lesions of the oral mucosa
K25 Stomach ulcer
K26 Duodenal ulcer
K35 Acute appendicitis
K65 Peritonitis
L02 Skin abscess, boil and carbuncle
M86.6 Other chronic osteomyelitis
N34 Urethritis and urethral syndrome
N39.0 Urinary tract infection without established location
N41.0 Acute prostatitis
N41.1 Chronic prostatitis
N49 Inflammatory diseases of the male genital organs, not elsewhere classified
N70 Salpingitis and oophoritis
N70.0 Acute salpingitis and oophoritis
N70.1 Chronic salpingitis and oophoritis
N71 Inflammatory diseases of the uterus, except the cervix
N73.9 Inflammatory diseases of the female pelvic organs, unspecified
R53 Malaise and fatigue
T30 Thermal and chemical burns of unspecified location
T79.3 Post-traumatic wound infection, not elsewhere classified
Z100* CLASS XXII Surgical practice
Z40 Preventive surgery
Z50.2 Rehabilitation for alcoholism
Z50.3 Drug rehabilitation
Z51.0 Radiotherapy course
Z51.1 Chemotherapy for neoplasm
Z54.0 Convalescent period after surgery
Z73.6 Restrictions in activity caused by decreased ability to work
Z98.8 Other specified postsurgical conditions

Compound

Powder for preparing a solution for intramuscular administration	1 fl.
active substance:
aminodihydrophthalazindione sodium (Galavit®)	50 mg
100 mg

Rectal suppositories	1 sup.
active substance:
aminodihydrophthalazindione sodium (Galavit®)	50 mg
100 mg
excipients: vitepsol H15 (fatty acid glycerides) - 575 mg; Witepsol W35 (fatty acid glycerides) – 575 mg

Sublingual tablets	1 table
active substance:
aminodihydrophthalazindione sodium (Galavit®)	25 mg
excipients: sorbitol - 315 mg; starch - 140 mg; lactose - 100 mg; calcium stearate - 5 mg; talc - 15 mg; racementhol (menthol) - 0.1 mg

Galavit tablets: composition

The activity of the drug against viral infections is explained by the presence of sodium aminodihydrophthalazinedione in the active substance. The patented name of this component is Galavit. The auxiliary components are:

starch;
lactose;
sorbitol;
menthol;
calcium stearate.

The drug is an immunomodulator that has an anti-inflammatory effect. You can find the drug in the pharmacy not only in the form of tablets, but also in the form of rectal suppositories.

Pharmacodynamics

Rectal suppositories, 50 mg, 100 mg; sublingual tablets

The mechanism of action of the drug is associated with the ability to influence the functional and metabolic activity of macrophages.

In inflammatory diseases, the drug reversibly inhibits for 6–8 hours the excessive synthesis of TNF, IL-1 and other proinflammatory cytokines, reactive oxygen species by hyperactivated macrophages, which determine the degree of inflammatory reactions, their cyclicity, as well as the severity of intoxication. Normalization of the functional state of macrophages leads to the restoration of the antigen-presenting and regulatory functions of macrophages and a decrease in the level of autoaggression. Stimulates the bactericidal activity of neutrophil granulocytes, enhancing phagocytosis and increasing the body's nonspecific resistance to infectious diseases.

Powder for preparing a solution for intramuscular administration

The mechanism of action of the drug is associated with its ability to influence the functional and metabolic activity of phagocytic cells (monocytes/macrophages, neutrophils, natural killer cells). In addition, Galavit® normalizes antibody formation and indirectly stimulates the production of endogenous interferons (IFN-α, IFN-γ).

In inflammatory diseases, the drug reversibly inhibits for 6–8 hours the excessive synthesis of hyperactivated macrophages TNF-α, IL-1, IL-6 and other proinflammatory cytokines, reactive oxygen species, the level of which determines the degree of inflammatory reactions, their cyclicity, as well as the severity of intoxication and level of oxidative stress. Normalization of the functional state of macrophages leads to the restoration of the antigen-presenting and regulatory functions of macrophages and a decrease in the level of autoaggression. Stimulates the bactericidal activity of neutrophil granulocytes, enhancing phagocytosis and increasing the body's nonspecific resistance to infectious diseases.

Indications of the drug Galavit®

Powder for preparing a solution for intramuscular administration

As an immunomodulatory and anti-inflammatory agent in the complex therapy of immunodeficiency conditions in adults and adolescents from 12 years of age:

peptic ulcer of the stomach and duodenum;

viral hepatitis;

chronic recurrent diseases caused by the herpes virus;

diseases caused by the human papillomavirus;

infectious and inflammatory urogenital diseases (urethritis of chlamydial and trichomonas etiology, chlamydial prostatitis, acute and chronic salpingoophoritis, endometritis);

purulent-inflammatory diseases of the pelvic organs;

postoperative rehabilitation of patients with uterine fibroids;

complications of the postoperative period in women of reproductive age;

postoperative purulent-septic complications and their prevention (including in cancer patients);

chronic recurrent furunculosis, erysipelas;

asthenic conditions, neurotic and somatoform disorders, decreased physical performance (including among athletes);

mental, behavioral and post-withdrawal disorders in alcohol and drug addiction;

inflammatory diseases of the mucous membrane of the mouth and throat, periodontal diseases.

In adults and adolescents over 12 years of age in monotherapy:

acute and chronic infectious and inflammatory diseases of the gastrointestinal tract, accompanied by intoxication and/or diarrhea;

chronic urogenital infections, incl. when carrying out immunorehabilitation measures during the inter-relapse period in order to maintain clinical remission.

As an immunomodulatory and anti-inflammatory agent in the complex therapy of immunodeficiency conditions in children over 6 years of age:

purulent surgical diseases (burn lesions, recurrent furunculosis, chronic osteomyelitis, gangrenous appendicitis with omentitis, peritonitis, purulent pleurisy);

frequent recurrent diseases of the respiratory tract and ENT organs of bacterial and viral etiology (frequent ARVI, bronchitis, pneumonia, chronic tonsillitis, chronic otitis media, chronic adenoiditis).

Rectal suppositories, 50 mg

As an immunomodulatory and anti-inflammatory agent in complex therapy in children aged 6–12 years:

infectious intestinal diseases accompanied by intoxication and/or diarrhea;

peptic ulcer of the stomach and duodenum;

viral hepatitis;

chronic recurrent diseases caused by the herpes virus;

diseases caused by the papilloma virus;

purulent surgical diseases (burn lesions, recurrent furunculosis, chronic osteomyelitis, gangrenous appendicitis with omentitis, peritonitis, purulent pleurisy);

asthenic conditions, neurotic and somatoform disorders, decreased physical performance;

postoperative purulent-septic complications and their prevention (including in cancer patients);

treatment and prevention of urogenital infections of bacterial and viral etiology;

inflammatory diseases of the mucous membrane of the mouth and throat, periodontal diseases;

prevention of influenza and acute respiratory infections.

Rectal suppositories, 100 mg

As an immunomodulatory and anti-inflammatory agent in the complex therapy of immunodeficiency conditions in adults and adolescents over 12 years of age:

infectious intestinal diseases accompanied by intoxication and/or diarrhea;

peptic ulcer of the stomach and duodenum;

viral hepatitis;

chronic recurrent diseases caused by the herpes virus;

diseases caused by the papilloma virus;

infectious and inflammatory urogenital diseases (urethritis of chlamydial and trichomonas etiology, chlamydial prostatitis, acute and chronic salpingoophoritis, endometritis);

purulent-inflammatory diseases of the pelvic organs;

postoperative rehabilitation of patients with uterine fibroids;

complications of the postoperative period in women of reproductive age;

postoperative purulent-septic complications and their prevention (including in cancer patients);

chronic recurrent furunculosis, erysipelas;

asthenic conditions, neurotic and somatoform disorders, decreased physical performance (including among athletes);

mental, behavioral and post-withdrawal disorders in alcohol and drug addiction;

inflammatory diseases of the mucous membrane of the mouth and throat, periodontal diseases;

nonspecific prevention and treatment of influenza and acute respiratory infections.

Galavit 50 mg 5 pcs. injection solution for intramuscular administration Selvim 1/5

pharmachologic effect

Immunomodulatory and anti-inflammatory agent.

Composition and release form Galavit 50 mg 5 pcs. injection solution for intramuscular administration Selvim 1/5

Pharmaceutical substance: sodium aminodihydrophthalazindione (Galavit®) - 50 or 100 mg.

Description of the dosage form

Crystalline powder - white or white with a yellowish tint.

Suppositories - from white to white with a yellowish tint, torpedo-shaped without visible inclusions on a longitudinal section.

Directions for use and doses

Intramuscularly. Before administration, the drug is diluted in 2 ml of water for injection or 0.9% sodium chloride solution. Methods of application, doses and duration of use are selected by the doctor depending on the diagnosis, severity of the disease, and age of the patient.

For gastric and duodenal ulcers in the acute period: 2 days, 200 mg once a day, then 100 mg at intervals of 72 hours. A course of 15-25 injections. In the chronic period: 5 days, 100 mg once a day, then 100 mg every 72 hours. Course of 20 injections.
For viral hepatitis: the initial dose is 200 mg once, then 100 mg 2 times a day until the symptoms of intoxication and inflammation subside. Subsequent continuation of the course of 100 mg at intervals of 72 hours. Course 20 - 25 injections.
For chronic recurrent diseases caused by the herpes virus: 100 mg daily for 5 injections, then 100 mg every other day for 15 injections.
For diseases caused by the papilloma virus: 5 days, 100 mg once a day, then 100 mg every other day, 15 injections. Course of 20 injections.
For urogenital diseases - urethritis of chlamydial and trichomonas etiology, chlamydial prostatitis: 1 day 100 mg twice, then 100 mg every other day. A course of 10-15 injections (depending on the severity of the pathological process).
For salpingoophoritis, endometritis in the acute period: 2 days, 200 mg once a day, then 100 mg at intervals of 72 hours, duration of use depends on the severity of the disease. There are a total of 20 injections per course. In the chronic period: 5 days, 100 mg once a day, then 100 mg every 72 hours. Course of 20 injections.
For acute and chronic purulent diseases of the pelvic organs: in the acute period - 1 day 200 mg once, 3 days 100 mg daily, then 100 mg every other day 5 injections. Course of 10 injections. In the chronic period – 5 days, 100 mg once a day, then 100 mg every 72 hours. Course of 20 injections.
For postoperative rehabilitation of patients with uterine fibroids and complications of the postoperative period in women of reproductive age: 5 days, 100 mg once a day, then 100 mg every other day. Course of 15 injections.
For the prevention and treatment of postoperative infectious complications in the pre- and postoperative period (including in cancer patients): prescribed 100 mg once a day, 5 injections before surgery, 5 after surgery, 100 mg every other day, and 5 injections of 100 mg. with an interval of 72 hours. For severe disease, the initial dose is 200 mg once or 100 mg 2 times a day. Course of 20 injections.
For chronic recurrent furunculosis, erysipelas: 5 days, 100 mg once a day, then 100 mg every other day. Course of 20 injections.
For asthenic conditions, neurotic and somatoform disorders, for mental, behavioral and post-abstinence disorders, in patients with alcohol and drug addiction: 5 days, 100 mg daily, then 100 mg every 72 hours. A course of 15-20 injections. To increase physical performance: 100 mg every other day – 5 injections, then 100 mg every 72 hours, course up to 20 injections.
For inflammatory diseases of the mucous membrane of the mouth and throat, periodontal diseases: initial dose of 100 mg daily for 5 injections, then 100 mg at intervals of 72 hours. Course of 15 injections.

In adults and adolescents over 12 years of age in monotherapy:

acute and chronic infectious and inflammatory diseases of the gastrointestinal tract, accompanied by intoxication and/or diarrhea: 200 mg once, then 100 mg 2 times a day until the symptoms of intoxication subside. It is possible to subsequently continue the course of 100 mg at intervals of 72 hours. A course of 20-25 injections.
chronic urogenital infections, including when carrying out immunorehabilitation measures during the inter-relapse period in order to maintain clinical remission: 100 mg every other day in a course of 10 injections.

In children over 6 years of age:

For purulent surgical diseases (burn lesions, recurrent furunculosis, chronic osteomyelitis, gangrenous appendicitis with omentitis, peritonitis, purulent pleurisy): children from 6 to 11 years old, one injection of 50 mg daily for 5 days, then one injection of 50 mg every other day within 10 – 15 days. Course 10-15 injections; children aged 12-18 years - treatment is carried out according to the same scheme in the form of intramuscular injections of 100 mg. When dressings, it is desirable to apply Galavit externally in the form of dressings with sterile napkins moistened with a 1% solution of Galavit in water for injection (in dressings with mash or water-soluble ointment dressings).
For frequent recurrent diseases of the respiratory tract and ENT organs of bacterial and viral etiology (frequent ARVI, bronchitis, pneumonia, chronic tonsillitis, chronic otitis, chronic adenoiditis): children from 6 to 11 years old, one injection of 50 mg daily for 5 days, then 50 mg once a day every other day for 10 – 15 days. A course of 10-15 injections. Children aged 12-18 years – treatment according to the same regimen in the form of intramuscular injections of 100 mg.

Pharmacodynamics

The mechanism of action of the drug is associated with its ability to influence the functional and metabolic activity of phagocytic cells (monocytes/macrophages, neutrophils, natural killer cells). In addition, Galavit normalizes antibody formation and indirectly stimulates the production of endogenous interferons (IFN-α, IFN-γ).

In inflammatory diseases, the drug reversibly inhibits for 6-8 hours the excessive synthesis of tumor necrosis factor-α, interleukin-1, interleukin-6 and other pro-inflammatory cytokines, reactive oxygen species by hyperactivated macrophages, the level of which determines the degree of inflammatory reactions, their cyclicity, as well as severity intoxication and level of oxidative stress. Normalization of the functional state of macrophages leads to the restoration of the antigen-presenting and regulatory functions of macrophages and a decrease in the level of autoaggression. Stimulates the bactericidal activity of neutrophil granulocytes, enhancing phagocytosis and increasing the body's nonspecific resistance to infectious diseases.

Pharmacokinetics

It is excreted from the body mainly through the kidneys. After intramuscular injection, the half-life is 30-40 minutes. The main pharmacological effects are observed within 72 hours.

Indications for use Galavit 50 mg 5 pcs. injection solution for intramuscular administration Selvim 1/5

As an immunomodulatory and anti-inflammatory agent in the complex therapy of immunodeficiency conditions in adults and adolescents from 12 years of age:

peptic ulcer of the stomach and duodenum;
viral hepatitis;
chronic recurrent diseases caused by the herpes virus;
diseases caused by the human papillomavirus;
infectious and inflammatory urogenital diseases (urethritis of chlamydial and trichomonas etiology, chlamydial prostatitis, acute and chronic salpingoophoritis, endometritis);
purulent-inflammatory diseases of the pelvic organs;
postoperative rehabilitation of patients with uterine fibroids;
complications of the postoperative period in women of reproductive age;
postoperative purulent-septic complications and their prevention (including in cancer patients);
chronic recurrent furunculosis, erysipelas.
asthenic conditions, neurotic and somatoform disorders, decreased physical performance (including in athletes); mental, behavioral and post-withdrawal disorders in alcohol and drug addiction;
inflammatory diseases of the mucous membrane of the mouth and throat, periodontal diseases.

In adults and adolescents over 12 years of age in monotherapy:

acute and chronic infectious and inflammatory diseases of the gastrointestinal tract, accompanied by intoxication and/or diarrhea;
chronic urogenital infections, including when carrying out immunorehabilitation measures during the inter-relapse period in order to maintain clinical remission.

As an immunomodulatory and anti-inflammatory agent in the complex therapy of immunodeficiency conditions in children over 6 years of age:

purulent surgical diseases (burn lesions, recurrent furunculosis, chronic osteomyelitis, gangrenous appendicitis with omentitis, peritonitis, purulent pleurisy);
frequent recurrent diseases of the respiratory tract and ENT organs of bacterial and viral etiology (frequent ARVI, bronchitis, pneumonia, chronic tonsillitis, chronic otitis media, chronic adenoiditis).

Contraindications

Individual intolerance; pregnancy and lactation; children under 6 years of age (no clinical experience of use).

Application Galavit 50 mg 5 pcs. injection solution for intramuscular administration of Selvim 1/5 during pregnancy and lactation

The drug is not prescribed to pregnant women, women during breastfeeding, and children under 6 years of age.

special instructions

There are no special measures.

Overdose

No cases of overdose have been reported.

Side effects Galavit 50 mg 5 pcs. injection solution for intramuscular administration Selvim 1/5

In rare cases, allergic reactions are possible.

Drug interactions

With simultaneous use, it is possible to reduce the course doses of antibiotics. There are no cases of incompatibility with other drugs.

Directions for use and doses

IM, rectal, sublingual.

Powder for preparing a solution for intramuscular administration

Before administration, the drug is diluted in 2 ml of water for injection or 0.9% sodium chloride solution. The method of administration, dose and duration of use are selected by the doctor depending on the diagnosis, severity of the disease, and age of the patient.

For peptic ulcer of the stomach and duodenum: in the acute period - 2 days, 200 mg once a day, then 100 mg at intervals of 72 hours. Course - 15-25 injections. In the chronic period - 5 days, 100 mg once a day, then 100 mg every 72 hours. Course - 20 injections.

For viral hepatitis: initial dose - 200 mg once, then 100 mg 2 times a day until the symptoms of intoxication and inflammation subside. Subsequent continuation of the course - 100 mg at intervals of 72 hours. Course - 20-25 injections.

For chronic recurrent diseases caused by the herpes virus - 100 mg daily for 5 injections, then 100 mg every other day for 15 injections.

For diseases caused by the papilloma virus: 5 days, 100 mg once a day, then 100 mg every other day, 15 injections. Course - 20 injections.

For urogenital diseases - urethritis of chlamydial and trichomonas etiology, chlamydial prostatitis: 1 day 100 mg twice, then 100 mg every other day. The course is 10–15 injections (depending on the severity of the pathological process).

For salpingoophoritis, endometritis: in the acute period - 2 days, 200 mg once a day, then 100 mg at intervals of 72 hours, the duration of use depends on the severity of the disease. A total of 20 injections per course. In the chronic period - 5 days, 100 mg once a day, then 100 mg every 72 hours. Course - 20 injections.

For acute and chronic purulent diseases of the pelvic organs: in the acute period - 1 day 200 mg once, 3 days 100 mg daily, then 100 mg every other day 5 injections. Course - 10 injections. In the chronic period - 5 days, 100 mg once a day, then 100 mg every 72 hours. Course - 20 injections.

For postoperative rehabilitation of patients with uterine fibroids and complications of the postoperative period in women of reproductive age: 5 days, 100 mg once a day, then 100 mg every other day. Course - 15 injections.

For the prevention and treatment of postoperative infectious complications in the pre- and postoperative period (including in cancer patients): 100 mg once a day, 5 injections before surgery, 5 injections after surgery, 100 mg every other day, and 5 injections of 100 mg with an interval of 72 hours. For severe disease, the initial dose is 200 mg once or 100 mg 2 times a day. Course - 20 injections.

For chronic recurrent furunculosis, erysipelas: 5 days, 100 mg once a day, then 100 mg every other day. Course - 20 injections.

For asthenic conditions, neurotic and somatoform disorders, mental, behavioral and post-withdrawal disorders, in patients with alcohol and drug addiction: 5 days, 100 mg daily, then 100 mg every 72 hours. Course: 15–20 injections.

To increase physical performance: 100 mg every other day, 5 injections, then 100 mg every 72 hours, course - up to 20 injections.

For inflammatory diseases of the mucous membrane of the mouth and throat, periodontal diseases: initial dose - 100 mg daily for 5 injections, then 100 mg at intervals of 72 hours. Course - 15 injections.

In monotherapy in adults and adolescents from 12 years of age

For acute and chronic infectious and inflammatory diseases of the gastrointestinal tract, accompanied by intoxication and/or diarrhea, 200 mg once, then 100 mg 2 times a day until the symptoms of intoxication are relieved. It is possible to subsequently continue the course of 100 mg at intervals of 72 hours. The course is 20–25 injections.

For chronic urogenital infections, incl. when carrying out immunorehabilitation measures during the inter-relapse period in order to maintain clinical remission: 100 mg every other day in a course of 10 injections.

In children over 6 years old

For purulent surgical diseases (burn lesions, recurrent furunculosis, chronic osteomyelitis, gangrenous appendicitis with omentitis, peritonitis, purulent pleurisy): children from 6 to 11 years old - 1 injection of 50 mg daily for 5 days, then 1 injection of 50 mg every other day within 10–15 days. Course - 10–15 injections; children aged 12–18 years - treatment is carried out according to the same scheme in the form of intramuscular injections of 100 mg. When dressings, it is desirable to use the drug Galavit® externally in the form of dressings with sterile wipes moistened with a 1% solution of Galavit® in water for injection (in dressings with mash or water-soluble ointment dressings).

For frequent recurrent diseases of the respiratory tract and ENT organs of bacterial and viral etiology (frequent ARVI, bronchitis, pneumonia, chronic tonsillitis, chronic otitis, chronic adenoiditis): children from 6 to 11 years old - 1 injection of 50 mg daily for 5 days, then 50 mg 1 time per day, every other day for 10–15 days. Course - 10–15 injections. Children aged 12–18 years - treatment according to the same regimen in the form of intramuscular injections of 100 mg.

Rectal suppositories, 100 mg

The suppository is released from the contour packaging and then inserted into the rectum. It is recommended to empty the intestines first.

The dose and duration of use of the drug depend on the nature, severity and duration of the disease.

For acute infectious intestinal diseases accompanied by diarrhea syndrome: initial dose - 2 supp. once, then 1 sup. 2 times a day until symptoms of intoxication subside. It is possible to continue the course of 1 supp. with an interval of 72 hours. Course - 20–25 supp.

For gastric and duodenal ulcers: in the acute period - 2 days, 2 supp. 1 time per day, then 1 sup. with an interval of 72 hours. Course - 15–25 supp. In the chronic period - 5 days, 1 sup. 1 time per day, then 1 sup. after 72 hours. Course - 20 supp.

For viral hepatitis: initial dose - 2 sup. once, then 1 sup. 2 times a day until symptoms of intoxication and inflammation subside. Subsequent continuation of the course - 1 sup. with an interval of 72 hours. Course - 20–25 supp.

For chronic recurrent diseases caused by the herpes virus - 1 supp. daily - 5 sup., then 1 sup. every other day - 15 supp.

For diseases caused by the papilloma virus - 5 days, 1 supp. 1 time per day, then 1 sup. in one day. Course - 20 supp.

For urogenital diseases (urethritis of chlamydial and trichomonas etiology, chlamydial prostatitis): 1 day, 1 supp. twice, then 1 sup. - in one day. Course - 10–15 supp. (depending on the severity of the pathological process).

For salpingoophoritis, endometritis: in the acute period - 2 days, 2 supp. 1 time per day, then 1 sup. with an interval of 72 hours. In the chronic period - 5 days, 1 sup. 1 time per day, then 1 sup. every 72 hours. Course - 20 supp.

For acute and chronic purulent diseases of the pelvic organs: in the acute period - 1 day, 2 supp. once, 3 days, 1 sup. daily, then 1 sup. every other day - 5 days. Course - 10 supp. In the chronic period - 5 days, 1 sup. 1 time per day, then 1 sup. every 72 hours. Course - 20 supp.

For postoperative rehabilitation of patients with uterine fibroids and complications of the postoperative period in women of reproductive age: 5 days, 1 supp. 1 time per day, then 1 sup. in one day. Course - 15 supp.

For the prevention and treatment of surgical complications in the pre- and postoperative period (including in cancer patients): 1 supp. 1 time per day - 5 supp. before surgery, 5 sup. - 1 sup. after surgery one day and 5 supp. - 1 sup. with an interval of 72 hours. For severe disease, the initial dose is 2 supp. once or 2 times a day, 1 sup. Course - 20 supp.

For chronic recurrent furunculosis, erysipelas: 5 days, 1 supp. 1 time per day, then 1 sup. in one day. Course - 20 supp.

For asthenic conditions, neurotic and somatoform disorders, mental, behavioral and post-abstinence disorders, in patients with alcohol and drug addiction: 5 days, 1 sup. daily, then 1 sup. after 72 hours. Course - 15–20 supp.

To increase physical performance: 1 supp. every other day - 5 sup., then 1 sup. after 72 hours, course - up to 20 sup.

For inflammatory diseases of the mucous membrane of the mouth and throat, periodontal diseases: initial dose - 1 supp. daily - 5 sup., then 1 sup. with an interval of 72 hours. Course - 15 supp.

For nonspecific prevention and treatment of influenza and acute respiratory infections: 1 supp. 1 per day. Course - 5 days.

Rectal suppositories, 50 mg

The suppository is released from the contour packaging and then inserted into the rectum. It is recommended to empty the intestines first.

For acute infectious intestinal diseases accompanied by diarrhea syndrome: initial dose - 2 supp. 50 mg once, then 1 supp. 2 times a day until symptoms of intoxication subside. It is possible to continue the course of 1 supp. with an interval of 72 hours. Course - 20 supp.

For chronic recurrent diseases caused by the herpes virus: 1 supp. daily for 5 days, then 1 sup. in one day. Course - 15 supp.

For diseases caused by the papilloma virus: 5 days, 1 supp. 1 time per day, then 1 sup. in one day. Course - 20 supp.

For purulent surgical diseases (burn lesions, recurrent furunculosis, chronic osteomyelitis, gangrenous appendicitis with omentitis, purulent pleurisy): 1 supp. daily - 5 days, then 1 sup. every other day for 10 days.

For asthenic conditions, neurotic and somatoform disorders: 5 days, 1 supp. daily, then 1 sup. after 72 hours. Course - 15 supp.

To increase physical performance: 1 supp. every other day a course of 5 supp.

For the prevention and treatment of surgical complications in the pre- and postoperative period (including in cancer patients): 1 supp. 1 time per day - 5 supp. before surgery, 5 - after surgery, 1 sup. every other day and 5 sup. with an interval of 72 hours. For severe disease, the initial dose is 2 supp. once or 2 times a day, 1 sup. Course - 20 supp.

In the treatment and prevention of urogenital infections of bacterial and viral etiology: 1 day, 1 supp. 2 times a day, then 1 sup. in one day. Course - 10–15 supp. (depending on the severity of the pathological process).

For inflammatory diseases of the mucous membrane of the mouth and throat, periodontal diseases: initial dose - 1 supp. daily - 5 sup., then 1 sup. with an interval of 72 hours. Course - 15 supp.

For the prevention of influenza and acute respiratory infections - 1 supp. 1 per day. Course - 5 supp.

Sublingual tablets

1 table each daily up to 4 times a day or 2 tablets. daily up to 2 times a day, depending on the diagnosis and severity of the disease.

For acute infectious intestinal diseases accompanied by diarrhea syndrome: initial dose - 2 tablets. once, then 1 tablet. 3-4 times a day until symptoms of intoxication subside for 3-5 days.

For peptic ulcer of the stomach and duodenum: in the acute period - the first 2 days - 1 table. 4 times a day, then every 3 days, 1 tablet. 4 times a day, course - 2-3 weeks. In the chronic period - 5 days, 1 tablet. 4 times a day, then every 3 days, 1 tablet. 4 times a day for up to 3 weeks.

For viral hepatitis of various etiologies: in the acute period of the disease, the initial dose is 2 tablets. 2 times a day until symptoms of intoxication and inflammation subside. It is possible to continue the course of 1 table. 4 times a day every 3 days for a course of up to 2-3 weeks.

For chronic recurrent diseases caused by the herpes virus: 1 table. 4 times a day for 10 days. Then 1 table. 4 times a day every other day for 10 days.

For diseases caused by the human papillomavirus: 5 days, 1 tablet. 4 times a day, then 1 tablet. 4 times a day every other day for a course of up to 2-3 weeks.

For urogenital diseases (urethritis of chlamydial and trichomonas etiology, chlamydial prostatitis): on the first day - 2 times 2 tablets, then 1 tablet. 4 times a day every other day for a course of up to 2 weeks (depending on the severity of the pathological process).

For salpingoophoritis, endometritis: in the acute period - 2 days, 2 tablets. 2 times a day, then 1 tablet. 4 times a day every 3 days for 3 weeks. In the chronic period - 5 days, 1 tablet. 4 times a day, then 1 tablet. 4 times a day every 3 days for a course of up to 2-3 weeks.

For acute and chronic purulent diseases of the pelvic organs: in the acute period on the first day - 2 tablets. 2 times a day, then 3 days 1 tablet. 4 times a day, then 1 tablet. 4 times a day every other day for 10 days. In the chronic period - 5 days, 1 tablet. 4 times a day, then 3-4 tablets. every 3 days for up to 3 weeks.

For postoperative rehabilitation of patients with uterine fibroids and complications of the postoperative period in women of reproductive age: 5 days, 1 tablet. 4 times a day, then 1 tablet. 4 times a day every other day for up to 2 weeks.

For purulent surgical diseases (burn lesions, chronic osteomyelitis, gangrenous appendicitis with omentitis, peritonitis, purulent pleurisy): 4 times a day, 1 tablet. for 5 days, then 1 tablet. 4 times every other day for up to 15 days.

For the prevention and treatment of surgical complications in the pre- and postoperative period (including in cancer patients): 1 table. 4 times a day for 5 days before surgery, for 10 days after surgery, 1 tablet. 4 times every other day and for 3 weeks, 1 tablet. 4 times every 3 days. In case of severe disease, take 2 tablets on the first day. 2 times a day.

For chronic recurrent furunculosis, erysipelas: 5 days, 1 tablet. 4 times a day, then 1 tablet. 4 times every other day for up to 3 weeks.

For asthenic conditions, neurotic and somatoform disorders, mental, behavioral and post-abstinence disorders, in patients with alcohol and drug addiction: 5 days, 1 tablet. 4 times a day, then 1 tablet. 4 times every 3 days for 3 weeks.

To increase physical performance: 1 table. 4 times every other day for 10 days, then 1 tablet. 4 times a day every 3 days for a course of up to 3 weeks.

For inflammatory diseases of the mucous membrane of the mouth and throat, periodontal diseases: initial dose - 1 table. 4 times a day for 5 days, then 1 tablet. 4 times a day every 3 days for a course of up to 3 weeks.

For the prevention of acute respiratory infections and influenza: 1 table. 2 times a day for a course of 5–10 days.

General information

Trade name Galavit®
Registration number LSR-008746/09

INN or group name Aminodihydrophthalazindione sodium

Chemical name 5-amino-1,2,3,4-tetrahydrophthalazine-1,4-dione sodium salt

Dosage form Sublingual tablets

Release form

Sublingual tablets, 25 mg. 10 or 20 sublingual tablets in blister packs made of polyvinyl chloride film and aluminum foil. 1, 2, 3 or 4 contour packages along with instructions for use in a cardboard box. 10, 20, 30, 40 or 50 contour packs with an equal number of instructions for use in a group pack

Compound

Active ingredient - sodium aminodihydrophthalazindione (Galavit®) 0.025 g, excipients - sorbitol 0.315 g, starch 0.14 g, lactose 0.1 g, calcium stearate 0.005 g, talc 0.015 g and racementol (menthol) 0.0001 g. Description The tablets are white with a yellowish tint, biconvex, without a score, with a menthol odor.

Pharmacotherapeutic group

Immunomodulatory and anti-inflammatory agent.

ATX code L03

Pharmacological properties

Pharmacodynamics

The mechanism of action of the drug is associated with its ability to regulate the functional and metabolic activity of innate and adaptive immune cells (monocytes, macrophages, neutrophils, natural killer cells, etc.). Galavit normalizes the phagocytic activity of monocytes/macrophages, the bactericidal activity of neutrophils and the cytotoxic activity of NK cells. At the same time, by restoring the reduced activity of innate and adaptive immune cells, the drug increases the body’s resistance to infectious diseases of bacterial, viral and fungal etiology, promotes faster elimination of the pathogen from the body, and reduces the frequency, severity and duration of infections.

In addition, Galavit normalizes antibody formation, increases the functional activity (affinity) of antibodies, and indirectly regulates the production of endogenous interferons (IFN-α, IFN-γ) by producer cells. In inflammatory diseases, the drug reversibly inhibits for 6-8 hours the excessive synthesis of tumor necrosis factor-α, interleukin-1, interleukin-6 and other pro-inflammatory cytokines by hyperactivated macrophages, the level of which determines the degree of inflammatory reactions, their cyclicity, as well as the severity of intoxication of the body.

Galavit reduces the production of reactive oxygen species by hyperactivated macrophages, thereby reducing the level of oxidative stress and protecting tissues and organs from the destructive effects of radicals. Normalization of excessively increased functional activity of phagocytic cells leads to the restoration of their antigen-presenting and regulatory functions, and a decrease in the level of autoaggression. The drug is well tolerated and has no allergenic, mutagenic, embryotoxic, teratogenic or carcinogenic effects. Pharmacokinetics Excreted from the body mainly through the kidneys. When administered sublingually, the half-life is 30 minutes. The main pharmacological effects are observed within 72 hours.

Russia, 123290, Moscow, dead end Magistralny 1st, 5A, room. 91 Tel/fax 8-800-707-71-81 E-mail: [email protected] ; https://www.galavit.ru Address of production site 308013, Belgorod, st. Rabochaya, 14 Send claims to the address 123290, Moscow, dead end Magistralny 1st, 5A, room. 91. Tel. 8-800-707-71-81

Indications for use

In adults and adolescents over 12 years of age (including those with secondary immune deficiency) as an immunomodulatory and anti-inflammatory agent in complex therapy:

acute respiratory infections, diseases of the respiratory tract and ENT organs (including often recurrent ones) of bacterial and viral etiology (ARVI, influenza, bronchitis, pneumonia, tonsillitis, otitis, adenoiditis) and their prevention;
inflammatory diseases of the mucous membrane of the mouth and throat, periodontal diseases;
chronic recurrent diseases caused by the herpes virus;
decreased physical performance (including among athletes)

Directions for use and doses

Sublingually, 1 tablet up to 4 times a day or 2 tablets up to 2 times a day.

For acute respiratory infections, flu, bronchitis, pneumonia, tonsillitis, otitis, adenoiditis for treatment: 1 tablet 4 times a day. Course 5 days.
In case of chronic and frequent relapsing course, continue 1 tablet 4 times a day every other day for a course of up to 15 days.
For prevention: 1 tablet 2 times a day. Course 5-10 days.
For inflammatory diseases of the mucous membrane of the mouth and throat, periodontal diseases: 1 tablet 4 times a day for 5 days. Then 1 tablet 4 times a day after 3 days for a course of up to 3 weeks.
For chronic recurrent diseases caused by the herpes virus: 1 tablet 4 times a day for 10 days. Then 1 tablet 4 times a day every other day for 10 days.
To increase physical performance: 1 tablet 4 times every other day for 10 days, then 1 tablet 4 times a day after 3 days for a course of up to 3 weeks.

Treatment with Galavit can be started at any stage of the disease. Use the drug according to the indications, the method of administration and in the doses indicated in the instructions. If after these courses of treatment there is no improvement, or the symptoms worsen, or new symptoms appear, you should consult your doctor.

Precautionary measures

Contraindications

Individual intolerance, intolerance to galactose, fructose, lactase deficiency or glucose-galactose malabsorption, pregnancy and breastfeeding, children under 12 years of age.

Use during pregnancy and breastfeeding

The drug is contraindicated for pregnant women and women during breastfeeding.

Side effects

In rare cases, allergic reactions are possible. If you experience the side effects listed in the instructions or they get worse, or you notice any other side effects not listed in the instructions, tell your doctor.

Overdose

No cases of overdose have been reported.

Interaction with other drugs

With simultaneous use, it is possible to reduce the course doses of antibiotics. Galavit allows you to increase the effectiveness of antibiotic therapy and reduce its damage

The drug contains sorbitol; patients with rare hereditary pathologies associated with fructose and sorbitol intolerance should not take the drug.

Impact on the ability to drive vehicles and machinery

The drug does not affect the ability to drive vehicles or operate machinery.

Shelf life, storage conditions

Storage conditions: Store at a temperature not exceeding 25 ° C, in a place protected from light. Keep out of the reach of children.

Shelf life: 3 years. Do not use after the expiration date indicated on the carton.

Conditions for dispensing from pharmacies Dispensed without a prescription.

Release form

Powder for preparing a solution for intramuscular administration. In a bottle, 50 mg, 100 mg. 3 or 5 fl. in a cardboard box.

Rectal suppositories, 50 mg, 100 mg. In blister pack, 5 pcs. 1 or 2 contour packages in a cardboard box.

Sublingual tablets, 25 mg. In blister packs made of PVC film and aluminum foil, 10 or 20 pcs. 1, 2, 3 or 4 contour packages in a cardboard box. 10, 20, 30, 40 or 50 contour packs in group packaging.